Apricus Bio (APRI) Announces Pre-Clinical Data Showing Significant Improvement in Solubility and Absorption of NexACT(R)-Based Small Molecule Drugs
Nov. 19, 2010 (Business Wire) — Apricus Biosciences, Inc., (“Apricus Bio”) (Nasdaq: APRI) today announced data from animal studies showing that the NexACT® technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption. A total of 10 small molecule therapeutic drugs with known low solubility and/or permeability, according to the Biopharmaceuticals (“BCS”) Classification System, were selected for these studies, and represented the following classes: anti-inflammatory drugs, diuretics, anti-hypertensives, antibiotics, anti-psychotics, anti-Parkinson agents and proton pump inhibitors.
The BCS, developed by Professor Gordon L. Amidon from the College of Pharmacy at the University of Michigan, separates drugs into four quadrants depending on their solubility and permeability. Class 1 drugs are high solubility and high permeability, Class 2 low solubility and high permeability, Class 3 high solubility and low permeability, and Class 4 low solubility and low permeability. In the Apricus Bio studies, the compounds that showed the most improvement when formulated with the NEXACT technology were in Classes 2 and 4, where solubility is a determining factor.
Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio, stated, “Drugs are classified according to their solubility and permeability. This early data shows that the inclusion of NexACT can significantly improve the oral delivery of some small molecules by positively affecting their solubility, which affects absorption. Over time, this could open up exciting new partnership opportunities, especially for promising drug candidates that did not reach, or successfully pass through clinical development, because of poor solubility. Our goal is to make a major breakthrough in the utilization of NexACT to improve and/or enable the delivery of difficult-to-absorb compounds.”
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including its approved drug erectile dysfunction treatment, Vitaros®, as well as compounds in development from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to replicate pre-clinical study results in subsequent human clinical studies, enter into partnership agreements and successfully execute business plans. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K and subsequent quarterly reports filed on Form 10-Q. Copies of these reports are available from the SEC’s website or without charge from the Company.
Apricus Biosciences
Edward Cox, 858-848-4249
V.P. Investor Relations
or
Apricus Bio Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
TraderPower Featured Companies
- Aditxt Inc. (NASDAQ: ADTX)
- Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)
- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
- Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)
- Cepton Inc. (NASDAQ: CPTN)
- CISO Global, Inc. (NASDAQ: CISO)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Correlate Infrastructure Partners Inc. (OTCQB: CIPI)
- Cybin Inc. (NYSE American: CYBN) (NEO: CYBN)
- Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)
- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)
- EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)
- Flora Growth Corp. (NASDAQ: FLGC)
- Freight Technologies Inc. (NASDAQ: FRGT)
- HeartBeam Inc. (NASDAQ: BEAT)
- Golden Matrix Group Inc. (NASDAQ: GMGI)
- InMed Pharmaceuticals Inc. (NASDAQ: INM)
- Knightscope, Inc. (NASDAQ: KSCP)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)
- Mullen Automotive Inc. (NASDAQ: MULN)
- QSAM Biosciences Inc. (OTCQB: QSAM)
- Tingo Inc. (OTC: TMNA)
- Vision Energy Corp. (OTCQB: VENG)
Top Small Cap Market News
- $FLGC CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space
- $ADTX Researchers ID Substance That Could Make Autoimmune Disease Treatment Possible
- $AZMCF Copper Sales Help Ivanhoe Register Record 2022 Profits
- $CPTN InvestorNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Announces CEO’s Panel Participation in Upcoming EV/Auto Tech Virtual Conference
- $CISO InvestorNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Releases Preliminary Quarter, FY Financial Report
- $CNSP Normalizing Blood Vessels in Tumors Could Improve Brain Cancer Immunotherapy
- $QBTS D-Wave Quantum Inc. (NYSE: QBTS) Combines Power of Quantum Computing with Cloud, Machine Learning, to Fuel Business Efficiencies, Innovation
- $QBTS InvestorNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Launch of New Hybrid Solver Plug-In
- $BEAT HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults
- $KSCP InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds to Growing Orders, Marks 75th Stop in Robot Roadshow Schedule
- $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust R&D Programs
- $MUX MiningNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Positioned to Advanced Los Azules, Address Rising Demand for Copper
- $MULN InvestorNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Enters Licensing Agreement with Qiantu Motors to Manufacture, Distribute EV Supercar
Recent Posts
- $MULN InvestorNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Enters Licensing Agreement with Qiantu Motors to Manufacture, Distribute EV Supercar
- $MUX MiningNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Positioned to Advanced Los Azules, Address Rising Demand for Copper
- $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust R&D Programs
- $KSCP InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds to Growing Orders, Marks 75th Stop in Robot Roadshow Schedule
- $BEAT HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults
- $QBTS InvestorNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Launch of New Hybrid Solver Plug-In
- $QBTS D-Wave Quantum Inc. (NYSE: QBTS) Combines Power of Quantum Computing with Cloud, Machine Learning, to Fuel Business Efficiencies, Innovation
- $CNSP Normalizing Blood Vessels in Tumors Could Improve Brain Cancer Immunotherapy
Recent Comments
Archives
- March 2023
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009